Literature DB >> 33428807

Breast cancer stem cells: A review of their characteristics and the agents that affect them.

Naing L Shan1, Yoosub Shin2, Ge Yang1, Philip Furmanski1,3, Nanjoo Suh1,3.   

Abstract

The evolving concept that cancer stem cells (CSCs) are the driving element in cancer development, evolution and heterogeneity, has overridden the previous model of a tumor consisting of cells all with similar sequentially acquired mutations and a similar potential for renewal, invasion and metastasis. This paradigm shift has focused attention on therapeutically targeting CSCs directly as a means of eradicating the disease. In breast cancers, CSCs can be identified by cell surface markers and are characterized by their ability to self-renew and differentiate, resist chemotherapy and radiation, and initiate new tumors upon serial transplantation in xenografted mice. These functional properties of CSCs are regulated by both intracellular and extracellular factors including pluripotency-related transcription factors, intracellular signaling pathways and external stimuli. Several classes of natural products and synthesized compounds have been studied to target these regulatory elements and force CSCs to lose stemness and/or terminally differentiate and thereby achieve a therapeutic effect. However, realization of an effective treatment for breast cancers, focused on the biological effects of these agents on breast CSCs, their functions and signaling, has not yet been achieved. In this review, we delineate the intrinsic and extrinsic factors identified to date that control or promote stemness in breast CSCs and provide a comprehensive compilation of potential agents that have been studied to target breast CSCs, transcription factors and stemness-related signaling. Our aim is to stimulate further study of these agents that could become the basis for their use as stand-alone treatments or components of combination therapies effective against breast cancers.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  breast cancer; cancer stem cells; differentiation; pluripotency

Mesh:

Substances:

Year:  2021        PMID: 33428807      PMCID: PMC7855917          DOI: 10.1002/mc.23277

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  249 in total

1.  Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway.

Authors:  Soheila Koohestanimobarhan; Siamak Salami; Vahideh Imeni; Zeinab Mohammadi; Omid Bayat
Journal:  J Cell Biochem       Date:  2018-09-06       Impact factor: 4.429

Review 2.  Krüppel-like factors in breast cancer: Function, regulation and clinical relevance.

Authors:  Jianping Zhang; Guangliang Li; Lifeng Feng; Haiqi Lu; Xian Wang
Journal:  Biomed Pharmacother       Date:  2019-12-17       Impact factor: 6.529

Review 3.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

4.  Differentiation therapy for solid tumors.

Authors:  Wen Ping Xu; Xin Zhang; Wei Fen Xie
Journal:  J Dig Dis       Date:  2014-04       Impact factor: 2.325

5.  CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.

Authors:  P-K Lo; D Kanojia; X Liu; U P Singh; F G Berger; Q Wang; H Chen
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

Review 6.  The role of CD44 in epithelial-mesenchymal transition and cancer development.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Hua Wu; Qian Liu; Richard G Pestell; Kongming Wu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

Review 7.  Triple-negative breast cancer: is there a treatment on the horizon?

Authors:  Hui Yao; Guangchun He; Shichao Yan; Chao Chen; Liujiang Song; Thomas J Rosol; Xiyun Deng
Journal:  Oncotarget       Date:  2017-01-03

8.  Bioactive Immunomodulatory Compounds: A Novel Combinatorial Strategy for Integrated Medicine in Oncology? BAIC Exposure in Cancer Cells.

Authors:  Bruna Corradetti; Salvatore Vaiasicca; Mauro Mantovani; Edy Virgili; Massimo Bonucci; Ivano Hammarberg Ferri
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

9.  Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression.

Authors:  Alyssa La Belle Flynn; Benjamin C Calhoun; Arishya Sharma; Jenny C Chang; Alexandru Almasan; William P Schiemann
Journal:  Nat Commun       Date:  2019-08-14       Impact factor: 14.919

Review 10.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

Authors:  Ramesh Butti; Sumit Das; Vinoth Prasanna Gunasekaran; Amit Singh Yadav; Dhiraj Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more
  3 in total

1.  Molecular Radiotherapy with 177Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro.

Authors:  Tao Huang; Jae Sam Lee; Alexander L Klibanov; Jiang He
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

2.  MicroRNA-18 facilitates the stemness of gastric cancer by downregulating HMGB3 though targeting Meis2.

Authors:  Yingjun Zhang; Weijian Lin; Weiping Jiang; Zhenfa Wang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Ursolic Acid Decreases the Proliferation of MCF-7 Cell-Derived Breast Cancer Stem-Like Cells by Modulating the ERK and PI3K/AKT Signaling Pathways.

Authors:  Gi Dae Kim
Journal:  Prev Nutr Food Sci       Date:  2021-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.